xBiologix designs, builds, customizes & validates biomarker profiling products & protocols for solid tissue imaging using our patent pending, click-chemistry reagents & conventional multiplexed immunofluorescent platforms. Our multispectral imaging, antibody-oligo products characterize tumor microenvironments & surrounding tissue with a single incubation of (4-20) primary antibodies & gentle signal removal/re-imaging protocol. This simplified, “one pot” staining protocol is uniquely suited to conventional autostaining & multispectral imaging platforms, & amenable to workflow standardization & validation supporting research & clinical laboratory processes. | xBiologix provides multiplexed, fluorescent microscopy products and service supporting our spatial biology customers. Our ready-to-use, platform independent, pre-validated, massively multiplexed immunofluorescent IHCs (mIHC/IF) protocol radically simplifying the published cyclic protocols— a.k.a cycIF. We seek to partner with small oncology focused drug developers who want to reliably identify potential trial participants by screening patient resected tumors for the candidate’s mode of action.
WIENER LAB.
We develop, manufacture and market integrated solutions that enable IVD diagnostics in more than 50 countries around the world. We offer a broad line of products for clinical laboratories and blood banks that enable accurate and timely diagnoses. We generate key and relevant information for medical decision making, understanding the laboratory as a crucial link in the health chain. | We develop, manufacture and market integrated solutions that enable IVD diagnostics in more than 50 countries around the world. We offer a broad line of products for clinical laboratories and blood banks that enable accurate and timely diagnoses. We generate key and relevant information for medical decision making, understanding the laboratory as a very important player in the health system. | Wiener lab. is an innovation-driven multinational from Argentina, with over six decades of experience in the in vitro diagnostics (IVD) industry. With a presence in more than 50 countries, the company continues to grow across Latin America, South Asia, and Europe. Its mission is to deliver smart, reliable, and accessible diagnostic solutions for healthcare systems worldwide. At the heart of its innovation engine is the Centre for Research and Biotechnology (CIBio), where a diverse team of scientists and engineers leads the development of new technologies. The company promotes open innovation by fostering strategic partnerships with academic institutions, regulatory bodies, and clinical collaborators. Wiener lab. actively seeks global partners for OEM manufacturing, technology transfer, and co-development projects. These collaborations are essential for enhancing technological capabilities and providing quicker, more adaptable solutions to meet evolving healthcare demands. The product portfolio includes clinical chemistry, molecular biology, hematology, hemostasis, immunology, urinalysis, chemiluminescence, and ESR, all developed in certified manufacturing facilities that comply with ISO and FDA requirements.
Wales Cymru (Welsh Government)
Wales is a self-governing country of the UK and the Welsh Government is the devolved Government for Wales. The Welsh Government’s decision-making powers within a small and joined-up country mean we can act fast. They also mean we are responsible for our own economic development, so you won’t find a more pro-business Government anywhere. Wales has a strong industrial heritage that has shaped our confident, creative and ambitious economy of today. Wales means business.
Valerian Chem Private Ltd
VProteomics, Valerian Chem Pvt. Ltd. to Showcase Advanced Mass Spectrometry Solutions at BIO International Convention 2025 We are excited to announce that VProteomics, Valerian Chem Pvt. Ltd. will be participating in the Innovative India Pavilion at the BIO International Convention 2025, taking place from June 16–19, 2025, at the Boston Convention & Exhibition Center, USA. As a leading provider of high-end mass spectrometry services, VProteomics specializes in proteomics, metabolomics, and clinical diagnostics, catering to academic institutions, medical researchers, and pharmaceutical companies. Our state-of-the-art laboratory in Noida is equipped with the latest mass spectrometry infrastructure, enabling us to deliver precise and reproducible results. Our Core Competencies: Discovery & Targeted Proteomics: Comprehensive protein analysis to elucidate complex biological processes. Advanced Metabolomics: In-depth metabolite profiling to understand metabolic pathways and disease mechanisms. Clinical Mass Spectrometry: Diagnostic services including biomarker detection, enzyme analysis, and toxicology testing, facilitating early disease diagnosis and personalized medicine. Biologics Characterization: Detailed analysis of biologic therapeutics to ensure efficacy and safety. We invite our esteemed clients, collaborators, and partners to visit our booth at the Innovative India Pavilion to explore potential collaborations and learn more about our contributions to the global biotech landscape. Event Details: Event: BIO International Convention 2025 Dates: June 16–19, 2025 Location: Boston Convention & Exhibition Center, Boston, USA Pavilion: Innovative India Pavilion For more information about our services, please visit our website: www.vproteomics.com We look forward to connecting with you in Boston!
UK Health Security Agency
Come and talk to us at the UK Pavilion (765) about how we can help support your research and development requirements with consultancy and assay development from our world-renowned experts, our wide range of specialist services and diagnostics, our high containment facilities and our ability to provide high throughput laboratory analysis capacity. The UK Health Security Agency (UKHSA) is responsible for planning, preventing and responding to external health threats, and providing intellectual, scientific and operational leadership at national and local level, as well as globally. We are an executive agency, sponsored by the Department of Health and Social Care. The Agency operates a network of laboratories across England including centres of excellence at Colindale (London) and Porton (Wiltshire), providing a range of clinical, reference and public health microbiology services including bacteriology, mycology, virology, immunology, and genomics. Leadership in communicable diseases, field epidemiology and rapid investigations is also supported by real-time surveillance and analysis and emergency preparedness and response activities delivered via regional health protection teams. All our laboratories have active research and development interests, including the evaluation of novel vaccines, antimicrobials, and in vitro diagnostics, and all our clinical laboratories can assist with access to clinical samples, including novel and emerging pathogens. Our key services include conducting 4 million regional laboratory tests, analysing 350,000+ reference samples, performing 190,000 genomic sequences annually, handling 40,000 rare pathogen referrals, and processing 500,000 radiation dosimeters yearly. We also offer advanced diagnostic capabilities, world-leading expertise in vaccine evaluation and phage translation/application, and have one of the strongest behavioural science units in UK Government. We employ 3,000 scientists across 30+ disciplines and we maintain strong partnerships with 500+ universities globally. Our intellectual property portfolio includes 165 patents and 64 trademarks. UKHSA’s unique position as a public health organisation combines scientific expertise, laboratory infrastructure, and research capabilities. Our income generated from commercial services strengthens our core health security work, while our collaborative approach with industry and academia drives public health benefits and economic growth. We provide a comprehensive range of specialist health security services and products, addressing challenges in public health protection and disease surveillance. These consist of a range of clinical, reference and public health microbiology services including bacteriology, mycology, virology, immunology, and genomics. Leadership in communicable diseases, field epidemiology and rapid investigations is also supported by real-time surveillance and analysis and emergency preparedness and response activities delivered via regional health protection teams. Our key services include: Radiation personal dosimetry service (processing ~500,000 dosimeters annually) Regional laboratory testing (4 million tests supporting NHS diagnostics and public health outbreaks) Reference services (350,000+ samples for specific pathogen analysis) Genomic sequencing (90,000 next-generation and 100,000 Sanger sequencing samples annually) Rare and Imported Pathogen Laboratory services (40,000 NHS referrals) UKHSA’s competitive advantages include: One of the strongest behavioural science and insights functions in UK Government Employment of 3,000 scientists across 30+ scientific disciplines Extensive intellectual property portfolio (165 patents and 64 registered trademarks) Strong partnerships with academia (500+ universities globally) Advanced diagnostic capabilities and accelerator programme World-leading expertise in phage translation and application High containment facilities for in vivo and in vitro research (BSL 3 and 4) Our value proposition lies in our unique position as a public health organisation combining scientific expertise, extensive laboratory infrastructure, and research capabilities. The income generated from commercial services strengthens our core health security services, while our collaborative approach with industry and academia drives both public health benefits and economic growth.
TubeWriter
TubeWriter labeling systems is a full-feature instrument for printing directly at high-speed on the sides and caps of plastic, glass, and curved surfaces, including tubes, vials, slides, plates and custom labware. It is designed to address automating laboratory printing for assays, protocols and experiments. TubeWriter labeling withstands the harshest of lab conditions; resistant to chemical solvents and surviving long-term storage at -80C and liquid nitrogen. | TubeWriter is an automated labeling systems that prints directly on the surface of any labware eliminating the need for sticky labels. For laboratories that perform medium to high-throughput applications struggling with manual labeling or paper labels, the TubeWriter prints directly on the sides and caps of tubes, vials, plates and unique labware. TubeWriter prints text, images, and barcodes using UV-curable ink that withstands extreme lab conditions, most harsh chemicals and long-term storage at -80C and liquid nitrogen.
The Hong Kong Polytechnic University
With 85 years of proud tradition and ranking among the world’s top 100 institutions, The Hong Kong Polytechnic University (PolyU) aspires to be a leading university with world-class research and education. Our holistic professional education, which embraces new technologies, entrepreneurship, and service-learning, aims to nurture graduates who not only possess a competitive edge in their disciplinary knowledge, but also develop into socially responsible leaders. As a university with a strong emphasis on societal impact, PolyU is devoted to providing interdisciplinary solutions for major social challenges through advanced research and knowledge transfer activities. Our innovations have opened up new horizons in space, improved health and well-being, boosted economic efficiency, and fostered sustainability for a better world. Our strong culture of knowledge transfer and entrepreneurship helps transform our research breakthroughs into real-world applications. Looking to the future, PolyU will continue its pursuit of excellence, cultivating talent who serve society with passion, and contributing to the development of Hong Kong as an international innovation and technology hub in the Greater Bay Area. We will carry on manifesting the spirit of the University’s Motto: To learn and to apply, for the benefit of mankind. | With 86 years of proud tradition and ranking among the world’s top 100 institutions, The Hong Kong Polytechnic University (PolyU) aspires to be a leading university with world-class research and education. Our holistic professional education, which embraces new technologies, entrepreneurship, and service-learning, aims to nurture graduates who not only possess a competitive edge in their disciplinary knowledge, but also develop into socially responsible leaders. As a university with a strong emphasis on societal impact, PolyU is devoted to providing interdisciplinary solutions for major social challenges through advanced research and knowledge transfer activities. Our innovations have opened up new horizons in space, improved health and well-being, boosted economic efficiency, and fostered sustainability for a better world. Our strong culture of knowledge transfer and entrepreneurship helps transform our research breakthroughs into real-world applications. Looking to the future, PolyU will continue its pursuit of excellence, cultivating talent who serve society with passion, and contributing to the development of Hong Kong as an international innovation and technology hub in the Greater Bay Area. We will carry on manifesting the spirit of the University’s Motto: To learn and to apply, for the benefit of mankind. | The Hong Kong Polytechnic University (PolyU) aspires to be an innovative world-class university that pursues excellence in education, research and knowledge transfer. Driven by its motto, “To learn and to apply, for the benefit of mankind”, the University nurtures socially responsible professionals and leaders and pursues world-leading research and innovation for societal benefits. | With 85 years of proud tradition and ranking among the world’s top 100 institutions, The Hong Kong Polytechnic University (PolyU) aspires to be a leading university with world-class research and education. We strive in inter-disciplinary research and impactful innovations to address real-world challenges.
Staburo GmbH
Staburo GmbH is a data science company, specialized in biostatistics, programming (with R and SAS), data management and bioinformatics for healthcare projects. Our core competencies include Clinical Statistics, Translational Medicine & Biomarkers, Phase I, Data Transparency & Disclosure Services and Bioinformatics. Our customers are CROs (with small or no biometry department inhouse), biotech companies, international pharmaceutical companies (7 of the top 20) and medical device manufacturers.
Reference Medicine
Reference Medicine was founded to solve the problem of oncology diagnostic developers struggling to access the specimens they need reliably, affordably, and without the hassle experienced with typical CROs and biobanks. We work with collection sites worldwide to provide high-quality specimens that are specifically formatted to meet all stages and types of assay development – from early development through to test maintenance, and across slide, tissue, liquid biopsy, and image-based cancer detection. We’re here to make it easy for you to get the samples you need to build the next life-saving cancer test. | Reference Medicine was founded by researchers who were tired of traditional biospecimen sourcing getting in the way of science. We make it easy to find the specimens you need at a fraction of the cost – so your team can get on to building the next big thing in healthcare. | Reference Medicine was founded to solve the problem of oncology diagnostic developers struggling to access the specimens they need reliably, affordably, and without the hassle experienced with typical CROs and biobanks. We work with a variety of collection sites worldwide to standardize and build a just-in-time bank of high-quality specimens that are specifically formatted to meet all stages and types of oncology assay development – from early development through to test maintenance, and across slide, tissue, liquid biopsy, and image-based cancer detection. Our unique approach translates each donation into numerous specimens across our product line, including matched tissue and fluid, individual or matched sets of tissue blocks, and image assets with genomic and/or proteomic characterization data – enabling one individual donation to reach up to 10 different assay development teams. By reducing the numerous barriers to accessing these critical biospecimens, we help patients give meaning to their disease and enable teams at the forefront of cancer research to build the next life-saving diagnostic. | Reference Medicine was founded to solve the problem of oncology diagnostic developers struggling to access the specimens they need reliably, affordably, and without the hassle experienced with typical CROs and biobanks. We work with a variety of collection sites worldwide to standardize and build a just-in-time bank of high-quality specimens that are specifically formatted to meet all stages and types of oncology assay development – from early development through to test maintenance, and across slide, tissue, liquid biopsy, and image-based cancer detection. Our unique approach translates each donation into numerous specimens across our product line, including matched tissue and fluid, individual or matched sets of tissue blocks, and healthy fluids – enabling one individual donation to reach up to 10 different assay development teams. By reducing the numerous barriers to accessing these critical biospecimens, we help patients give meaning to their disease and enable teams at the forefront of cancer research to build the next life-saving diagnostic.
Quanttrace
Quanttrace: Pioneering Non-Invasive Therapeutic Drug Monitoring Quanttrace is a spin-off from the Laboratory of Neuroengineering at the National University of San Martín (UNSAM, Buenos Aires, Argentina). We are pioneers in non-invasive therapeutic drug monitoring, developing devices that personalize healthcare without interfering with patients’ daily lives. Successful pharmacological treatment relies on patient adherence. However, even perfect adherence can’t prevent plasma level variability due to individual differences in absorption, metabolism, and sensitivity. Personalized medicine aims for optimal drug levels tailored to each individual, especially for medications with narrow therapeutic ranges (such as oncologic drugs, antipsychotics, anticonvulsants, and antibiotics). Our challenge at Quanttrace is to provide the pharmaceutical and biotech industries with in-situ methods for measuring plasma concentrations without disrupting daily routines. Our technology is wearable, non-invasive, and works in everyday environments without laboratory equipment. Data is processed on a mobile device, and results are immediate. Quanttrace merges complex signal analysis and AI tools with advanced medicinal chemistry, allowing patients and caregivers to monitor plasma drug concentration at home and communicate directly with their doctors. This represents a significant advancement towards precision medicine and in-situ dose control, ensuring optimal treatment adherence. At Quanttrace we are currently conducting preclinical trials in small and large animals to validate our technology. At this stage, we have filed a provisional patent to protect our innovation. Right now we are actively seeking investment to refine our development and successfully conclude our preclinical trials and go into a clinical phase of research. We are open to hearing from investors who wish to partner with us in this innovative and exciting research pipeline. keywords: personalized medicine, precision medicine, precision healthcare, patient monitoring device, in-situ dose control, therapeutic drug monitoring, artificial intelligence, AI, medicinal chemistry, at home monitoring.